

For Official Use

DEELSA/ELSA/WP1/ARD/A(2002)1/REV1



Organisation de Coopération et de Développement Economiques
Organisation for Economic Co-operation and Development

06-Jun-2002

English - Or. English

**DIRECTORATE FOR EDUCATION, EMPLOYMENT, LABOUR AND SOCIAL AFFAIRS
EMPLOYMENT, LABOUR AND SOCIAL AFFAIRS COMMITTEE**

Working Party on Social Policy. Ageing-Related Diseases.

**WHAT IS BEST AND AT WHAT COST?
OECD STUDY ON CROSS-NATIONAL DIFFERENCES OF AGEING-RELATED DISEASES:
CONCLUDING WORKSHOP**

DRAFT ANNOTATED AGENDA

**To be held at the International Conference Centre, 19 Avenue Kléber, 75016 Paris
from 20 to 21 June 2002, starting at 9h30 on the first day.**

For further information, please contact Pierre Moise, Tel: (33 1) 45 24 94 11, e-mail: pierre.moise@oecd.org, Lynelle Moon, Tel: (33 1) 45 24 88 45, e-mail: lynelle.moon@oecd.org, or Stephane Jacobzone, Tel: (33 1) 45 24 85 56, e-mail: stephane.jacobzone@oecd.org

JT00127735

Document complet disponible sur OLIS dans son format d'origine
Complete document available on OLIS in its original format

**DEELSA/ELSA/WP1/ARD/A(2002)1/REV1
For Official Use**

English - Or. English

**WHAT IS BEST AND AT WHAT COST?
OECD STUDY ON CROSS-NATIONAL DIFFERENCES OF AGEING-RELATED DISEASES:
CONCLUDING WORKSHOP
DRAFT ANNOTATED AGENDA
PARIS, 20-21 JUNE 2002**

**International Conference Centre, 19 Avenue Kléber, 75016 Paris
Starting at 9h30 on the first day.**

This annotated agenda is intended to provide guidance for speakers and discussants for the various sessions. In particular, it includes an expanded introduction of the topics of discussion for the final panel session the second day.

This workshop is the culmination of the Ageing-Related Diseases (ARD) study, an international study that has examined over the last three years the treatments, costs and outcomes of a number of diseases significant for older people in OECD countries. The workshop will bring together senior experts, health economists and health policy analysts, policy makers and researchers from the 21 countries that participated in the study. The workshop will focus on discussing the implications of the study both for research, and for health and ageing policy.

The main objectives are:

- To present a summary of the key findings from the combined disease analysis of the ARD study.
- To provide a forum for discussion of the policy and research implications of the study.
- To identify the key areas for potential improvements in health system performance, including gaps in information and analysis, and need for further data.

The workshop will focus on issues revealed by a disease-based analysis that contribute to our understanding of health system performance, in particular the role played by differing health systems and economic incentives between countries. The workshop is intended both as a learning and a working forum. There will be a mix of plenary sessions, panel discussions and interactions with the audience.

There will be a separate theme for each session. The majority of the sessions will include a perspective based on the results from the ARD study, and one or two other presentations on the theme of the session. Following these presentations, discussants will provide a commentary on the key issues raised by the speakers. The session will then be opened up for questions and comments from the audience.

A number of papers will be or are being produced for the workshop and are to be available through the OECD OLIS system. These papers are accompanied by a * symbol in the current draft. The full list of papers with the corresponding OECD OLIS codes is included in an ANNEX. For those experts who do not have access to OLIS, these papers will be sent electronically in advance of the workshop. Papers contributed by speakers and participants will be made available as room documents.

DAY 1 MORNING

The first morning will be devoted to an introduction of the project results and a number of thematic discussions.

OPENING SESSION**9.30**

Opening Remarks	<i>Martine Durand, Deputy Director OECD Directorate for Education, Employment, Labour and Social Affairs</i>
Goals of Workshop	<i>Professor David Wise, Harvard University, USA (Workshop Chair)</i>

SESSION 1: INTRODUCTION TO THE RESULTS OF THE ARD STUDY 10.00-11.15

The purpose of this session is to provide an introduction to the main results of the study. The ARD study has explored relationships between health care systems, institutional arrangements, and patterns of treatment, expenditure and outcomes. The study demonstrates that medical practice can be influenced by economic incentives across countries and that this is likely to explain some of the differences observed at a macroeconomic level. However, the intricacies of each of the diseases need to be reviewed and discussed in order to obtain a full understanding of the results.

• Project Introduction*	<i>Stéphane Jacobzone (OECD)</i>
• Summary results for the three diseases	
– Ischaemic Heart Disease*	<i>Pierre Moïse (OECD)</i>
– Stroke*	<i>Lynelle Moon (OECD)</i>
– Breast Cancer*	<i>Stéphane Jacobzone (OECD)</i>
• A perspective on disease studies	<i>Alan Garber (Stanford University, USA)</i>
• Discussants	<i>Isabelle Durand-Zaleski (HITEQ/Faculté Médicale de Créteil, FRA) Teresa Di Fiandra (Ministry of Health, ITA)</i>

The session will begin with a brief introduction of the ARD project's goals and achievements to date, with brief summaries of each of the disease analyses, with 10 minutes allotted to each. Mr. Garber will then offer a general perspective on the contribution of international disease-based studies to our knowledge of the field.

Following the presentations, two discussants will each have 7 minutes. Ms. Durand-Zaleski will offer a discussion from the clinical viewpoint, while Ms. Di Fiandra will offer a perspective from a national health policy maker.

**SESSION 2: WHY DO DIFFERENT COUNTRIES SPEND
DIFFERENT AMOUNTS ON HEALTH CARE?**

11.45-13.15

The purpose of this session is to address differences in health expenditure across countries, as one of the key goals of the ARD project was to contribute to the understanding of these cross country differences. Existing analyses, which have concentrated on aggregate economic and systemic determinants of spending, have left much unexplained. In addition, the full value of medical care and its contribution to well-being has rarely been addressed as part of the macroeconomic approach. The discussion is also hampered by difficulties in obtaining a clear analytic framework for comparing prices and outputs -- and therefore real expenditure -- across countries.

Session Chair: Mireille Elbaum (DREES, France)

• Macroeconomic analysis of the differences in expenditure	<i>Bengt Jönsson (Centre for Health Economics, SWE)</i>
• The value of medical care	<i>David Cutler (Harvard University, USA)</i>
• Can we understand differences of unit costs across countries	<i>Jack Triplett (Brookings Institution, USA)</i>
• Discussants	<i>Unto Häkkinen (STAKES, FIN) Alberto Holly (IEMS, SWI)</i>

The first presentation by Mr. Jönsson will provide an overview of recent macroeconometric analyses of variations in health expenditure across countries. Mr. Cutler will discuss the value of medical care from a wider economic and social perspective, reassessing the contribution of good health to the well being of nations, and the ways in which various health care systems can contribute to producing health across countries. Mr. Triplett will address the issue of measuring prices and costs in health care, with a particular focus on the difficulties of addressing this issue from an international perspective.

It is expected that each presentation will take 15 minutes. Following the presentations, two discussants involved in the ARD networks of experts will then open the discussion, with 7 minutes each. The floor will then be open for questions from the audience.

LUNCH

13.30-14.45

DAY 1 AFTERNOON

Sessions 3a, 3b and 3c will be organised as three parallel sessions based around specific themes. A wrap-up session will be held at the end of the afternoon.

SESSION 3a: AGEING (Parallel session)**14.45-16.30**

The purpose of this session will be to understand the implications of ageing for health care systems and what analytical strategies can be developed to cope with ageing. The ARD study indicates that economic constraints in health systems have important implications on the availability of health care for older persons.

Session chair: Ilija Batljan, Ministry of Health and Social Affairs, Sweden

• Projecting future needs	<i>Mandeep Bains(European Commission)</i>
• ARD perspective: An ageing viewpoint	<i>Stéphane Jacobzone (OECD)</i>
• Outline for a Survey on Health, Ageing and Retirement in Europe (SHARE)	<i>Brigitte Santos-Eggimann (IUMSP, SWI) and Pierre-Yves Geoffard (DELTA-IEMS, FRA)</i>
• Discussants	<i>Simona Giampaoli (Istituto Superiore Di Sanita, ITA) Howard Oxley (OECD)</i>

The first presentation by Ms. Bains will set the scene, presenting long-term scenarios for health expenditure across European countries under various economic and social assumptions. The magnitude of sensitivity of the projections to the assumptions will be underlined. Mr. Jacobzone will then offer a perspective based on the ARD study on age as a critical factor for determining patterns of admissions, treatments and outcomes across countries. Finally, Ms. Santos-Eggimann and Mr. Geoffard will introduce the outline for a survey on health, ageing and retirement in Europe, (SHARE), which in the future might offer a European counterpart to the US Health and Retirement Study.

It is expected that each presentation will take 15 minutes. Following the presentations, two discussants involved in the ARD networks of experts will then open the discussion, with 7 minutes each. The floor will then be open for questions from the audience.

SESSION 3b: TECHNOLOGY (Parallel session)**14.45-16.30**

The purpose of this session will be to investigate the drivers and implications of technological change for health care systems, drawing on the findings from this and related studies on the key role of technologies in understanding health expenditure trends. Current tools for assessing and regulating technology across countries will also be addressed.

Session chair: Annetine Gelijns, Columbia University, United States

• ARD perspective: The technology-health expenditure link	<i>Pierre Moïse (OECD)</i>
• A perspective from the Technological Change in Health Care (TECH) Global Research Network	<i>Vincenzo Atella (University of Rome Tor Vergata, ITA)</i>
• The role of technology assessment and regulation	<i>Clive Pritchard (OHE, UK)</i>
• Discussants	<i>Yuichi Imanaka (Kyoto University, JPN) Antonio Sarria (Instituto Carlos III, SPA)</i>

The session will begin with a presentation from Mr. Moïse, investigating the drivers of technological change and its implications for health care expenditures, illustrated with results from the ARD project. The next presentation, by Mr. Atella, will focus on the diffusion of health technology for treating a particular disease, acute myocardial infarction, from an international perspective. Mr. Pritchard will then present a paper discussing the role of technology assessment and regulation in the diffusion of health technology.

It is expected that each presentation will take 15 minutes. Following the presentations, two discussants involved in the ARD networks of experts will then open the discussion, with 7 minutes each. The floor will then be open for questions from the audience.

SESSION 3c: HEALTH OUTCOMES OVER THE CONTINUUM OF CARE**14.45-16.30**

This session broadens the discussion in two ways. Firstly, by extending the discussion to what we get for our money in terms of outcomes. Secondly, by addressing the whole continuum of care, including prevention, ambulatory care, acute care, and rehabilitation.

Session Chair: Margot Falcker, Ministry of Health, Germany

• Measuring "health and well being", an international perspective	<i>Ajay Tandon (WHO)</i>
• ARD perspective: health outcomes and the continuum of care	<i>Lynelle Moon (OECD)</i>
• Health outcomes: monitoring quality of care and patients' satisfaction	<i>Pia Maria Jonsson (NBHW, SWE)</i>
• Discussants	<i>Michael Goldacre (Oxford University, UK) Jack Tu (University of Toronto, CAN)</i>

The session includes three papers with three complementing perspectives. Ms. Moon will offer the perspective from the ARD project, Mr. Mathers will introduce the broad issues of measuring population health and wellbeing from WHO, and Ms. Jonsson will present a perspective on measuring quality of care and patient satisfaction using clinical outcome indicators and patient self-reports.

It is expected that each of the presentation of papers will take 15 minutes. Following the presentations, two discussants involved in the ARD networks of experts will then open the discussion, with 7 minutes each. The floor will then be open for questions from the audience.

SESSION 4: LESSONS FROM THE PROJECT**16.45-18.00*****Workshop Chair: David Wise, Harvard University, USA***

This session will begin with Rapporteurs' reports of the results of the three parallel workshops. Experts who have been involved in the Ageing-Related Diseases Study will then be invited to offer their views on the relevance of the project results drawing from the perspective of each of the three diseases.

Rapporteurs summaries:

Session 3a (Ageing)	<i>Diane Gibson (AIHW, AUS)</i>
Session 3b (Technology)	<i>Marie Christine Closon (UCL, BEL)</i>
Session 3c (Health Outcomes)	<i>Gregory Taylor (Health Canada, CAN)</i>
<i>ARD participants' perspectives</i>	
Ischaemic Heart Disease	<i>Grete Botten (Oslo University, NOR)</i>
Breast cancer	<i>Diane Lequet-Slama (DREES, FRA)</i>
Stroke	<i>Silvia Evers (Maastricht University, NET)</i>

The first half-hour will begin with summaries of the three parallel workshops. In the second half-hour, three experts closely involved in the study, Ms. Botten, Ms. Lequet-Slama and Ms. Evers, will provide brief presentations of what they believe to be the primary lessons to be learned from the project. A general discussion of lessons from the project on these three issues will conclude this session.

COCKTAIL 18 00

DAY 2

The second day will be devoted to discussions of the broad relevance of the results for research and policy. The goal is to provide an environment conducive to interactions between the speakers and the audience and to have a useful summing up of the implications for health and ageing policy.

SESSION 5: POLICY IMPLICATIONS**9.00-10.45*****Session Chair: Fabrizio Oleari, Ministry of Health, Italy***

This session will discuss the policy implications for health system performance of disease-based analyses. Different stakeholders can have varying perspectives on performance, physicians tend to emphasise a clinical issues, patients are interested in "quality of life", but also quality of medical amenities, while health policy makers are also interested in overall system performance indicators, such as, activity rates, but also in public health status. Discussants will draw on results from the ARD study, reflections by policy makers on information needs, and on other examples of international comparisons. Each participant will speak for 15 minutes.

• ARD perspective: understanding the performance of health systems	<i>Stéphane Jacobzone (OECD)</i>
• From Results to Action: The Implications For Health Policy Making	<i>Clive Smee (DOH, UK)</i>
• Information needs and the implications for monitoring health systems	<i>Richard Madden (AIHW, AUS)</i>
• The value of international perspectives in health and ageing policy	<i>Cathy Schoen (Commonwealth Fund, USA)</i>

Mr. Jacobzone will seek to use results from the ARD study to disentangle the various factors driving performance and how they can be reconciled between the micro and macro level. Mr. Smee will discuss the implications for health policy making drawing on a national health policy perspective. Mr. Madden will discuss the implications of this approach for monitoring health care systems and for developing the frameworks for comparable data, both within and across OECD countries. Finally, Ms. Schoen will further outline the value of international studies for health and ageing policy, drawing on the experience of the Commonwealth Fund in the field. Each speaker will speak for 15 minutes, to be followed by a general discussion.

SESSION 6: PANEL

11.15-13.00

The panel will be chaired by the workshop Chair: David Wise, Harvard University, USA

The panel discussion will focus on how research can best serve evidence-based policies while providing a strategic framework to address the implications of ageing for the health and well being of populations.

The following questions will be discussed during the roundtable:

- To which pressing policy issues related to ageing and health policy can a disease-based approach contribute?
- What specific data collection and measurement activities are needed if this disease-based approach is to be implemented ? Are these data already available, or are they still in the process of being developed?
- What additional contribution can international, cross-national analysis make ? Are cross-national benchmarks useful or valid?

Panellists

Richard Suzman (National Institute on Aging, USA)

Maria Theofilatou (European Commission, DG Research)

Peter Scherer (OECD)

Luis Bohigas (Ministry of Health and Consumption, SPA)

Jo de Cock (National Health Insurance Fund/INAMI, BEL)

Each panellist will make an initial intervention of no more than 10 minutes.

CLOSING REMARKS FROM THE WORKSHOP CHAIR.

13.00-13.15

ADJOURN

ANNEX:

The following documents will be the official documentation for the workshop. They will be made available through the OLIS system and sent electronically in advance. In principle, these OLIS documents will be available in both the official languages of the OECD (French and English). An additional set of documents, including the various materials supporting speakers' interventions will be distributed to participants at the workshop in their original language only.

Secretariat's documents	OLIS code
<i>Draft agenda (workshop program)</i>	DEELSA/ELSA/WP1/ARD/A(2002)1/FINAL
<i>Annotated agenda</i>	DEELSA/ELSA/WP1/ARD/A(2002)1/REV1/FINAL
<i>Project introduction</i>	DEELSA/ELSA/WP1/ARD(2002)1/FINAL
<i>Summary of Breast Cancer study</i>	DEELSA/ELSA/WP1/ARD(2002)2/FINAL
<i>Summary Ischaemic Heart Disease study</i>	DEELSA/ELSA/WP1/ARD(2002)3/FINAL
<i>Summary of Stroke study</i>	DEELSA/ELSA/WP1/ARD(2002)4/FINAL